A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029
Overview
- Phase
- Phase 2
- Intervention
- Pembrolizumab
- Conditions
- Non-Small-Cell Lung Cancer
- Sponsor
- Greg Durm, MD
- Enrollment
- 35
- Locations
- 5
- Primary Endpoint
- Progression Free Survival (PFS)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.
Detailed Description
OUTLINE: This is a multi-center study. Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m2 IV D1 and D8 every three weeks, docetaxel 75mg/m2 IV D1 every three weeks, or pemetrexed 500mg/m2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity. Administration Sequence: First Sequence - Pembrolizumab 200mg IV on Day 1 (cycle = 21 days) Administration Sequence: Second Sequence * Gemcitabine 1000mg/m\^2 IV on Days 1,8 (cycle = 21 days) * Docetaxel 75mg/\^2 IV on Days 1,8 (cycle = 21 days) * Pemetrexed 500mg/m\^2 IV on Day 1 (cycle -= 21 days)
Investigators
Greg Durm, MD
Sponsor-Investigator
Big Ten Cancer Research Consortium
Eligibility Criteria
Inclusion Criteria
- •Subjects must meet all of the following applicable inclusion criteria to participate in this study:
- •Written informed consent and HIPAA authorization for release of protected health information.
- •Age ≥ 18 years at the time of consent.
- •Histological or cytological evidence of stage IV NSCLC (any histology)
- •Subjects must have progressed on or after previous platinum-based chemotherapy. Chemotherapy may have previously been given with a PD-1 or PD-L1 inhibitor. Subjects must have also progressed on or after receiving any PD-1 or PD-L1 inhibitor (including pembrolizumab) as their most recent therapy and must have had at least a 3-month PFS on this therapy.
- •Subjects must be enrolled on the trial within 6 weeks of their last infusion of PD-1 or PD-L1 inhibitor therapy.
- •Subjects whose tumors harbor a mutation in EGFR exon 19 or 21 or have gene rearrangements in ALK or ROS1 must have already been treated with standard targeted therapies. NOTE: Subjects must also have progressed on or after platinum-containing combination chemotherapy.
- •ECOG Performance Status of 0 or 1 within 28 days prior to registration for protocol therapy.
- •Must be fit enough to receive next-line chemotherapy (either gemcitabine, docetaxel, or pemetrexed \[non-squamous only\]) according to the discretion of the treating physician.
- •Adequate laboratory values obtained within 28 days prior to registration for protocol therapy.
Exclusion Criteria
- •Subjects meeting any of the criteria below may not participate in the study:
- •Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
- •Active central nervous system (CNS) metastases. NOTE: Subjects who are symptomatic or have not undergone prior brain imaging must undergo a head computed tomography (CT) scan or brain MRI within 28 days prior to registration to exclude brain metastases.
- •Treatment with any investigational agent within 28 days prior to registration for protocol therapy with the exception of PD-1 or PD-L1 inhibitors.
- •No active second cancers with the exception of localized non-melanoma skin cancer, in-situ cervical or in-situ bladder cancer.
- •Evidence of active autoimmune disease requiring systemic treatment within the past 90 days or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
- •History of (non-infectious) pneumonitis requiring treatment with corticosteroids, evidence of interstitial lung disease or active, non-infectious pneumonitis.
- •History of an immune-related toxicity requiring treatment with corticosteroids during prior PD-1/ PD-L1 inhibitor treatment.
- •Diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy (excludes inhaled corticosteroids) within 7 days of study registration.
- •History of psychiatric illness or social situations that would limit compliance with study requirements.
Arms & Interventions
Pembrolizumab 200mg IV every 21 days
Patients who have been treated with a PD-1 or PD-L1 inhibitor and experienced a PFS of ≥3 months will be enrolled within 6 weeks of last dose of PD-1 or PD-L1 inhibitor. On Day 1 of each 3-week cycle, subjects will first receive pembrolizumab at a dose of 200mg IV every three weeks in combination with chemotherapy. Partner chemotherapy will be either gemcitabine 1000mg/m\^2 IV D1 and D8 every three weeks, docetaxel 75mg/m\^2 IV D1 every three weeks, or pemetrexed 500mg/m\^2 IV D1 every 3 weeks (pemetrexed for non-squamous histologies only). Subjects will continue to receive this combination until progression or intolerable toxicity.
Intervention: Pembrolizumab
Outcomes
Primary Outcomes
Progression Free Survival (PFS)
Time Frame: Time of treatment start until the criteria for disease progression or death, up to a maximum of 28 months
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter(LD) of target lesions; Progressive Disease (PD): \>= 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. PFS was defined as time from starting treatment to disease progression met by RECIST 1.1, start of additional anticancer therapy before progression, or death from any cause.
Secondary Outcomes
- Overall Survival (OS)(Time of treatment start until death or up to a maximum of 40 months)
- Progression Free Survival (PFS) by irRECIST(Time of treatment start until the criteria for disease progression or death, up to a maximum of 28 months)
- Clinical Benefit Rate (CBR)(Up to a maximum of 28 months)
- Number of Participants With Adverse Events(Adverse events were recorded from time of registration until 30 days after discontinuation of study drug(s) up to a maximum of 25 months.)
- Objective Response Rate (ORR)(Up to a maximum of 28 months)